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Abstract
Acute heart failure is an important clinical problem. In the USA approximately one million
patients are hospitalised annually for acute heart failure, and about 50% of these require
readmission within 6–12 months of discharge. Acute heart failure accounts for most hospital
admissions among patients over 65 years of age in the USA.
The prognosis in heart failure patients is poor. Mortality at five years is 25% and is higher
than in patients with myocardial infarction and some cancers. Despite major progress in
chronic heart failure management (Evidence Based Medicine) the treatment of acute heart
failure is still empirical. Large multi-centre studies on the pharmacotherapy of acute heart
failure are still lacking. The authors discuss management in acute heart failure concerning
guidelines of  the European Society of Cardiology from 2005 and modern pharmacotherapy.
(Folia Cardiol. 2006; 13: 275–282)
acute heart failure, pharmacotherapy of acute heart failure
Introduction
Acute heart failure is an important clinical pro-
blem. In the USA approximately one million patients
are hospitalised annually for acute heart failure, and
about 50% of these require readmission within
6–12 months of discharge. Acute heart failure ac-
counts for most hospital admissions among patients
over 65 years of age in the USA [1–3].
The prognosis in heart failure patients is poor.
Mortality at five years is 25% and is higher than in
patients with myocardial infarction and some can-
cers [3]. Although in-hospital mortality in patients
with worsening chronic heart failure is relatively
low, mortality or rehospitalisation within 60 days
stands at about 60% [3].
The underlying causes of acute heart failure
syndrome include structural changes in the heart
and vessels. The ageing of the population and ef-
fective treatment of more patients with acute co-
ronary syndromes have markedly increased the
number of patients with myocardial injury which
results in the development of heart failure.
Recent advances have greatly improved under-
standing of the physiology and risk factors for the
development of acute heart failure. It is increasin-
gly widely accepted that both acute and chronic
heart failure syndromes are caused by an interplay
of haemodynamic factors, activation of neurohormo-
nes and cytokines, fluid retention and redistribution
within the cardiovascular system [4, 5]. Knowled-
ge of the pathophysiological mechanisms has pro-
vided new directions in clinical trials with chronic
and acute heart failure patients.
Definition and pathophysiology
of acute heart failure
The European Society of Cardiology (ECS)
defines acute heart failure as a sudden onset of signs
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and symptoms of abnormal heart function [6]. It may
occur during or without preceding heart disease.
Heart failure may be associated with systolic or dia-
stolic failure, arrhythmia or pathological alterations
in preload or afterload. It is frequently a life-thre-
atening condition and requires immediate treat-
ment. Acute heart failure may develop as a new
onset condition or acute decompensation of chro-
nic heart failure [3, 6]. Patients with acute heart
failure may present with a spectrum of illnesses:
— acute heart failure which does not fulfil the cri-
teria of cardiogenic shock, pulmonary oedema
or hypertensive crisis;
— hypertensive acute heart failure in which the
symptoms of acute heart failure occur with high
blood pressure values and relatively normal left
ventricular function and with the presence of
radiological signs of pulmonary oedema;
— radiological signs of pulmonary oedema with
severe respiratory failure, pulmonary crepita-
tions, orthopnoea and arterial blood saturation
below 90%;
— cardiogenic shock: a state of inadequate tissue
perfusion due to cardiac dysfunction caused by
heart failure despite normal (corrected) prelo-
ad; there are no strict haemodynamic criteria
to account for differences in its incidence and
clinical course; cardiogenic shock is usually
characterised by low blood pressure values (sy-
stolic blood pressure < 90 mm Hg or mean blo-
od pressure decrease by > 30 mm Hg) and/or
low diuresis (< 0.5 ml/kg/h) at heart rate
> 60 bpm with or without vital organ failure;
cardiogenic shock is frequently related to low
output syndrome;
— markedly decreased cardiac output, usually
with accompanying tachycardia (arrhythmia,
thyrotoxicosis, anaemia, Paget’s disease etc.),
warm extremities, pulmonary congestion and
possibly low arterial blood pressure similar to
septic shock [6].
Acute heart failure may develop suddenly as
a complication of myocardial infarction, myocardi-
tis and valve defects. In over 70% of patients the
acute event occurs in the course of chronic heart
failure, for instance in the course of infection, stress,
inappropriate pharmacotherapy, rhythm disorders,
arterial hypertension or hormonal changes (such as
in thyrotoxicosis) [1, 3]. This situation is someti-
mes referred to as worsening chronic heart failure.
Acute heart failure should not be regarded as shock,
which may be due to many factors. If the shock is of
cardiac origin, acute heart failure should be taken into
account, as these two clinical entities may co-exist [4].
Advances in invasive cardiology and cardiac
surgery have significantly reduced mortality in pa-
tients with cardiogenic shock, but it remains high
nevertheless (35% on average) [1].
In acute heart failure left atrial pressure rises
suddenly, leading to pulmonary oedema. Venous
congestion ensues, leading to peripheral oedema
and hepatomegaly. The clinical manifestations of
acute heart failure include dyspnoea, orthopnoea,
cough and reduced exercise tolerance. Fluid reten-
tion increases body mass. There may be symptoms
related to low cardiac output, such as increased cre-
atinine, weakness, loss of consciousness, pallor,
cyanosis, nausea and vomiting [1].
Despite major progress in chronic heart failu-
re management (EBM, Evidence Based Medicine)
the treatment of acute heart failure is still empiri-
cal. Large multi-centre studies on the pharmacothe-
rapy of acute heart failure are still lacking [3].
The treatment of acute heart failure differs
from long-term medical care in patients with chro-
nic heart failure and requires admission to intensi-
ve care units.
It is important to monitor vital signs: pulse,
blood pressure, blood oximetry, diuresis, haemody-
namic parameters such as pulmonary capillary we-
dge pressure, left ventricular filling pressure, sys-
temic and pulmonary resistance and cardiac index.
Pharmacological treatment of acute heart failure
focuses on reducing myocardial oxygen demand,
improving contractility, reducing preload and after-
load and maintaining normal tissue perfusion [2]. In
decompensated heart failure the following drugs are
used: diuretics, positive inotropic drugs, vasodila-
tors and drugs enhancing renal perfusion (Table 1)
[3, 8, 9]. In acute heart failure an important objecti-
ve is to treat the underlying diseases and to remo-
ve the cause of the worsening of symptoms. Pa-
tients with ST-segment elevation myocardial infarc-
tion and cardiogenic shock should undergo
reperfusion treatment (percutaneous coronary in-
tervention or, if this is impossible, thrombolysis).
Patients with low output syndrome or structural
changes in the heart (for instance mitral valve re-
gurgitation or ventricular septal rupture) may need
surgical intervention [4, 8, 9].
The non-pharmacological management of acu-
te heart failure and its benefits are summarised in
Table 2.
In acute heart failure an important treatment
target is to establish an adequate blood oxygen le-
vel. The oxygen saturation should be between 95%
and 98% (a class I recommendation in the ESC
Guidelines 2005) [6]. In order to improve tissue
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oxygenation it is necessary to deliver oxygen to the
patients using mechanical ventilation, if indicated,
through face or nasal masks. In the early stage of
acute heart failure it is recommended that intrave-
nous morphine be administered (a class IIb recom-
mendation), usually with an anti-vomiting drug and,
in the case of fluid retention, intravenous diuretics
(class I recommendations) [6]. This approach is ef-
fective as proved in long-term studies, although
there has been no confirmation in controlled or ran-
domised clinical trials. The anxiolytic effects of
morphine reduce sympathetic activation in the cen-
tral nervous system, leading to a marked reduction
in preload and afterload [4]. Morphine and its deri-
vatives relieve anxiety and pain and reduce myocar-
dial oxygen demand [2, 10].
Intravenous diuretics and nitroglycerin redu-
ce preload and filling pressure [3, 6]. Loop diure-
tics (furosemide, bumetanide and torasemide), apart
from their diuretic effects, increase the production
of vasodilating prostaglandins, thus reducing preload
[2, 10]. Intravenous diuretics are recommended in
acute decompensated heart failure and accompanying
fluid retention (class I recommendation). Diuretics
normalise loading conditions and decrease neurohor-
monal activation in a short time. Thiazides and spiro-
nolactone may be combined with loop diuretics [6].
In acute left ventricular failure it is necessary to re-
duce fluid intake and maintain fluid balance.
Vasodilators such as sodium nitroprusside, ni-
troglycerin and enalaprilate reduce preload and after-
load [2, 3, 6]. Sodium nitroprusside is recommended
in patients with acute heart failure and increased
afterload, in other words in the presence of a hyper-
tensive crisis and mitral regurgitation (class I recom-
mendation) [6]. However, its chronic use may lead
to an accumulation of toxic metabolites (Table 3).
Widely used nitrates may cause tachyphylaxis
within 48 hours of administration. Other negative
effects include the development of tolerance to
high-dose nitrates after 16–24 h intravenous infu-
sion [6]. There is a lack of data on the safety and
efficacy of diuretics and nitrates in acute heart fa-
ilure [3, 6].
Two randomised trials have shown the effica-
cy of intravenous high-dose nitrates combined with
low-dose furosemide (class I recommendation) [6].
Positive inotropic drugs are recommended in
patients with peripheral hypoperfusion (hypotension,
renal impairment) (class IIa recommendation) [6].
Table 4 summarises the doses of positive ino-
tropic agents in compliance with the ESC guidelines.
Table 1. Pharmacotherapy of acute heart failure
Type of therapy Drugs
Intravenous diuretics Furosemide, torasemide, bumetanide
Intravenous vasodilators Sodium nitropruside, nitroglycerin, nesiritide
Intravenous positive inotropic drugs Dobutamine, dopamine, milrinone, enoximone,
epinephrine, norepnephrine, digoxin, levosimendan
Intravenous drugs enhancing renal perfusion Dopamine
Table 2. Non-pharmacological treatment of acute heart failure
Type of therapy Benefits
Oxygen therapy, artificial ventilation Increased oxygen delivery
Intra-aortic counterpulsation Decreased left ventricular end-diastolic pressure,
increased stroke volume, improved cardiac output
Biventricular pacing Ventricular contraction synchrony,
improved pump function of the heart
Mechanical left ventricular support devices Reduced ventricular work, unloading the heart
Interventions: percutaneous transluminal Recanalisation, improved perfusion,
coronary angioplasty, mitral valvuloplasty removal of the mechanical obstacle
Emergent cardiac surgery: coronary artery Improved perfusion, improved valve function
bypass grafting, surgery for heart valve defects,
heart transplant
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The following positive inotropes are used: digoxin,
dobutamine, isoproterenol, ibopamine, prenalterol,
xamoterol, epinephrine, norepinephrine, amrinone,
milrinone, enoximone, piroximone and vesnarino-
ne [3, 6, 7]. However, positive inotropic agents cau-
se side effects. They increase myocardial oxygen
demand and have pro-arrhythmic effects and a ne-
gative influence on the long-term prognosis [3, 6, 7].
Dobutamine may be ineffective in patients who have
been receiving beta blockers. In a recent OPTIME
— CHF study (the Outcomes of Prospective Trial
of Intravenous Milrinone for Exacerbations of Chro-
nic Heart Failure) milrinone used for the treatment
of decompensated heart failure insignificantly incre-
ased the incidence of arrhythmias and hypotension
as compared to placebo [7, 11].
Dobutamine and milrinone do not shorten the
hospital stay of patients with acute heart failure but
they may increase mortality, especially in patients
with ischaemic heart disease [3]. The benefits of di-
goxin in acute heart failure include an increased car-
diac index (CI), a reduced heart rate (CO), left ven-
tricular filling pressure and right atrial pressure [3].
Acute heart failure is a condition requiring
prompt intervention to improve the circulatory ha-
emodynamics. The available treatments are asso-
ciated with various side effects, such as neurohor-
monal activation, hypotension, arrhythmias and in-
creased myocardial ischaemia [2, 7]. Newer and
safer drugs may soon be used for the treatment of
acute heart failure, including calcium sensitisers,
recombinant B-type natriuretic protein, vasopepti-
dase inhibitors, endothelin antagonists and vaso-
pressin antagonists [1, 3, 4, 6, 7, 12–25].
Calcium sensitisers
Levosimendan and nesiritide are used for the
treatment of decompensated heart failure in many
countries.
Levosimendan increases the sensitivity of tro-
ponin C to calcium and activates ATP-dependent
potassium channels. It inhibits phosphodiesterase
III (PDE III) and is characterised by vasodilating and
positive inotropic properties [7, 12]. Levosimendan
dilates coronary and peripheral vessels through the
activation of ATP-dependent potassium channels.
It improves myocardial contractility with no effect
on intracellular calcium concentration. The drug
increases cardiac output and decreases pulmonary
capillary wedge pressure. Levosimendan does not
increase myocardial oxygen demand and is not as-
sociated with an increased risk of arrhythmias or
myocardial ischaemia. Nor is there a reduction in
Table 4. The European Society of Cardiology recommended dosage of positive inotropic drugs in
acute heart failure
Positive intropic drug Recommended intravenous dose
Dobutamine 2–20 mg/kg/min (b+)
Dopamine < 3 mg/kg/min: renal effect (d+)
3–5 mg/kg/min: positive inotropic action (b+)
 > 5 mg/kg/min (b+), vasopressor (a+)
Milrinone Bolus 25–75 mg/kg over 10–20 min followed by 0.375–0.75 mg/kg/min
Enoximone Bolus 0.275–0.75 mg/kg, followed by 1.25–7.5 mg/kg/min
Levosimendan Bolus 12–24 mg/kg over 10 min, followed by 0.1 mg/kg/min (max 0.2 mg/kg/min)
Norepinephrine 0.2–1 mg/kg/min
Epinephrine Bolus 1 mg, followed by 0.05–0.5 mg/kg/min
Table 3. Recommended dosage of vasodilators in patients with acute heart failure according to the
guidelines of the European Society of Cardiology 2005
Vasodilator Recommended intravenous dose
Nitroglycerin Initially 20 mg/min, may be up-titrated to 200 mg/min
Isosorbide dinitrate Initially 1 mg/h, may be up-titrated to 10 mg/h
Sodium nitroprusside 0.3–5 mg/kg/min
Nesiritide Bolus 2 mg/kg + infusion 0.015–0.03 mg/kg/min
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long-term survival in patients with acute heart
failure [3, 6]. Levosimendan also has positive lusi-
tropic affects, improving both systolic and diastolic
function. It reduces pulmonary capillary wedge
pressure by as much as 50% and increases cardiac
output by 40% in a dose-dependent manner. High
doses of levosimendan slightly increase the heart
rate [12, 17, 23]. The safety profile of levosimen-
dan seems more advantageous than that of dobuta-
mine. A multi-centre randomised study demonstra-
ted that a six-hour infusion of levosimendan impro-
ved circulatory haemodynamics in patients with
acute heart failure [17].
Levosimendan may be used in combination
with beta blockers. It has been found to be safer than
dobutamine [7].
In a multi-centre randomised LIDO study
(Efficacy and Safety of Intravenous Levosimendan
Compared with Dobutamine in Severe Low-Output
Heart Failure) haemodynamic improvement was
achieved in 28% of patients with acute heart failu-
re receiving levosimendan and in 15% of patients
treated with dobutamine (p = 0.022). At one month
after acute heart failure mortality was halved in pa-
tients receiving levosimendan (8% vs. 17%; p = 0.49).
At 180 days mortality in patients receiving levosi-
mendan was 26% in contrast to 38% in patients
receiving dobutamine, the difference being statisti-
cally significant (p = 0.029). Levosimendan was
more efficacious than standard dobutamine [7].
In the RUSSLAN study (Randomised Study on
the Safety and Effectiveness of Levosimendan in
Patients with Left Ventricular Failure after an Acute
Myocardial Infarct) levosimendan was also more
advantageous in patients with myocardial infarction
and concomitant heart failure [7, 24].
An ongoing REVIVE II study (Randomised,
Multi-centre Evaluation of Intravenous Levosimen-
dan Efficacy Versus Placebo in the Short Term Tre-
atment of Decompensated Heart Failure) has been
designed to evaluate the efficacy of intravenous le-
vosimendan in patients with decompensated heart
failure. Levosimendan is recommended in patients
with the symptoms of low cardiac output, in the
absence of arterial hypotension (class of recommen-
dations II) [6].
Natriuretic peptides in acute heart failure
There are four major natriuretic peptides: atrial
natriuretic peptide (ANP), which is synthesised in
the atria, brain natriuretic peptide (BNP), which is
synthesised in the ventricles, C-type natriuretic
peptide (CNP), which is synthesised in the brain and
the recently discovered Dendroaspis, which is de-
tectable in blood serum and the atrial myocardium
[26]. In patients with heart failure plasma ANP and
BNP levels are markedly increased. The natriure-
tic, diuretic, vasodilating and fibrosis-inhibiting
effects of natriuretic peptides provide attractive po-
ssibilities in the treatment of heart failure. In con-
trast to loop diuretics and many vasodilators, na-
triuretic peptides inhibit rather than stimulate the
renin-angiotensin-aldosterone system, which appe-
ars to have a major effect on the long-term efficacy
of heart failure treatment. Natriuretic peptides re-
duce myocardial ischaemia and modulate vessel
growth. A model of acute heart failure in dogs sho-
wed that exogenous BNP protected against an in-
crease in plasma renin activity in contrast to con-
trol animals [4, 25].
Administered intravenously nesiritide, a re-
combinant form of B-type natriuretic protein, incre-
ases intracellular cGMP concentration. The drug
has diuretic, natriuretic and vasodilating properties.
It dilates veins and arteries, including the coronary
vessels and decreases pulmonary capillary wedge
pressure [26]. Nesiritide also has beneficial effects
on hormonal activity as it decreases aldosterone and
endothelin-1 levels. The drug does not increase
myocardial oxygen demand, has no positive inotro-
pic effects and does not influence heart rate. It has
no pro-arrhythmic properties [2, 26]. Nesiritide
improves the echocardiographic parameters of dia-
stolic function and relieves symptoms in patients
with acute heart failure. It also increases glomeru-
lar filtration, inhibits the renin-angiotensin-aldoste-
rone system and induces natriuresis [4, 25, 26].
A multi-centre randomised PRECEDENT stu-
dy (The Prospective Randomised Evaluation of
Cardiac Ectopy with DobutaminE or Natrecor The-
rapy) was designed to compare the effects of Na-
trecor (nesiritide) and dobutamine on the inciden-
ce of ventricular arrhythmia in a group of 255 pa-
tients with severe heart failure requiring
intravenous vasoactive medication. After 24 h Hol-
ter monitoring the patients were given nesiritide
(0.015–0.03 mg/kg/min) or dobutamine (5 mg/kg/min).
Dobutamine was found to increase the number of
premature ventricular beats and mean heart rate.
In the dobutamine group there were significantly
more complex ventricular arrhythmias than in the
nesiritide group (p < 0.05) [22]. Nesiritide, in con-
trast to positive inotropes (such as dobutamine), has
no pro-arrhythmic effect. In a recently published
VMAC study (Vasodilator in the Management of
Acute Congestive Heart Failure) nesiritide reduced
pulmonary capillary wedge pressure faster and to
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a greater extent than did nitroglycerin. Nesiritide
was also better than placebo at reducing dyspnoea.
The reduction in dyspnoea was not statistically si-
gnificant as compared with nitroglycerin [3]. The
side effects of nesiritide included a marked decre-
ase in arterial blood pressure. In earlier studies with
higher doses of nesiritide hypotension was found
in 6–12% [8]. In VCAM study, in which nesiritide
was used in the currently recommended doses,
symptomatic hypotension occurred in 4% of pa-
tients, similar to those receiving nitroglycerin.
Nesiritide improves haemodynamics to a greater
extent than nitroglycerin and produces fewer side
effects. It does not lead to the tachyphylaxis obse-
rved in patients receiving nitroglycerin [2, 7, 26]. The
drug is efficacious and safe in patients with renal fa-
ilure [26]. Nesiritide was approved in the USA in
2001 for the treatment of acute decompensated he-
art failure. The ongoing BELIEVE study (B-type
Natriuretic Peptide and Post-myocardial Infarction
Left Ventricular Remodelling) is the first clinical trial
to analyse the cardioprotective properties of nesiri-
tide. Nesiritide inhibits fibroblast proliferation, af-
fects endothelial cells and inhibits aldosterone acti-
vity, thus preventing cardiac remodelling in patients
after acute myocardial infarction. Nesiritide, as
a multi-directional agent without serious side effects,
is promising in patients with acute heart failure. The
safety and efficacy of nesiritide in acute heart failure
have been demonstrated in a phase III study [26].
Endothelin receptor antagonists
in heart failure
Endothelin plays an important physiological
role as a regulator of cardiovascular function [27].
The endothelium possesses the ability to modula-
te vascular tone by the release of vasodilators (such
as endothelium-derived relaxing factor, bradykinin
and prostaglandins) and vasoconstrictors (such as
angiotensin II and endothelin). The interaction of
these locally produced factors with other systemic
vasoconstricting reflexes, and especially with the
sympathetic and RAA systems, results in the incre-
ase of vascular tone which is typical of heart failu-
re. Endothelin-1 increases pulmonary artery pres-
sure and pulmonary vascular resistance [1, 27]. The
concept of endothelial dysfunction in heart failure
is widely accepted.
Preliminary data show that endothelin anta-
gonists may improve left ventricular function, delay
or reverse unfavourable remodelling, decrease sys-
temic and pulmonary vascular resistance, improve
central haemodynamic parameters and prognosis [4, 13].
The effects of endothelin-1 are mediated by two
receptors: ETA and ETB. ETA receptors are
expressed in vascular smooth muscle cells, and the-
ir activation causes vasoconstriction. ETB recep-
tors are expressed in vascular endothelial cells, and
they induce nitric oxide-dependent vasodilation.
Some ETB receptors on vascular smooth muscle
cells may cause vasoconstriction. Understanding of
the role of endothelin-1 in heart failure has contri-
buted to the discovery of endothelin-1 receptor
antagonists. Endothelin-A and endothelin-B recep-
tor antagonists such as bosentan and tezosentan
increase left ventricular stroke volume [13]. Bosen-
tan, a non-selective ETA/ETB antagonist, dilates
systemic and pulmonary vessels in patients with
acute heart failure. Kiowski et al. used intravenous
bosentan or placebo in a randomised study in
24 patients with NYHA class III heart failure. Bo-
sentan was found to decrease arterial blood pres-
sure, pulmonary artery pressure, pulmonary capil-
lary wedge pressure, pulmonary and systemic va-
scular resistance and to increase the cardiac index
[14, 15]. Tezosentan is another non-selective ETA/
/ETB receptor antagonist.
Torre-Amione et al. [16] demonstrated that te-
zosentan rapidly improved peripheral and central
perfusion and was well tolerated. The effect of te-
zosentan on the cardiac index was seen as early as
at 30 minutes. Tezosentan decreased pulmonary ca-
pillary wedge pressure, pulmonary artery pressu-
re, pulmonary and systemic vascular resistance and
peripheral pressure and did not affect the heart rate.
In a multi-centre RITZ-2 study (The Randomi-
sed Intravenous TeZosentan Study) 292 patients
were randomised to receive tezosentan 50 mg/h or
100 mg/h or placebo for 24 hours after admission
for acute heart failure. The primary endpoint was
the change in cardiac index six hours after the start
of treatment, while secondary endpoints included
dyspnoea, worsening of heart failure at 24 hours and
death. Both doses of tezosentan increased the cardiac
index and decreased pulmonary capillary wedge pres-
sure significantly more than placebo (p < 0.0001).
Tezosentan was also associated with a dose-rela-
ted decrease in arterial blood pressure and no chan-
ges in heart rate. Patients who received tezosen-
tan were less likely to experience a worsening of
dyspnoea, and more likely to show clinical impro-
vement (p = 0.048). The safety profile of low dose
tezosentan was similar to that of placebo. In the
RITZ-1 and RITZ-2 study the side effects of tezo-
sentan resulted from vasodilation (hypotension,
headache and renal injury) and were probably
associated with the higher dose [19].
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A recently completed large, multi-centre inter-
national VERITAS study (Value of Endothelin
Receptor Inhibition with Tezosentan in Acute Heart
Failure Study) was designed to evaluate the short-
term efficacy of tezosentan in patients with severe
heart failure. The study was discontinued for futili-
ty. The results of the study were surprising: there
were no differences between tezosentan and pla-
cebo in dyspnoea reduction over the first 24 hours
of treatment. No differences were seen in the co-
urse of heart failure or mortality at 7 and 30 days.
Nor was there was any effect on six-month survi-
val either in patients receiving active treatment or
those receiving placebo. Tezosentan was not asso-
ciated with any clinical benefit despite clear haemo-
dynamic improvement (systolic blood pressure de-
creased by 6 mm Hg, improved cardiac index and
reduced systemic vascular resistance). The reasons
for this remain to be elucidated [28].
Other drugs
Vasopressin receptor antagonists, such as
OPC-41061 block the antidiuretic action of endoge-
nous vasopressin, thus increasing free water cle-
arance. Patients with heart failure have an incre-
ased level of antidiuretic hormones [21]. The
ACTIV-CHF study was designed to evaluate the ef-
fects of a selective vasopressin inhibitor (tolvaptan)
in patients hospitalised for heart failure with ejec-
tion fraction < 40%. An important symptom of wor-
sening heart failure is water retention, as manifest
by rapid body mass growth. In the ACTIV-CHF stu-
dy body weight at 24 hours decreased rapidly with
tolvaptan. At 60 days water loss was 2 l higher than
after placebo. Sodium concentration, as expected,
increased in patients receiving the active drug.
There were no changes in heart rate or blood pres-
sure and renal function was preserved. The rate of
readmission and worsening heart failure over
60 days was similar to placebo [21]. Vasopressin in-
hibitors may be indicated in patients at high risk of
death who have hyponatraemia, increased creatini-
ne levels and symptoms of progressive congestion
while staying in a hospital. The ongoing EVEREST
study (Efficacy of Vasopressin Antagonism in Heart
Failure: Outcome Study with Tolvaptan) is expec-
ted to provide a new insight into the treatment of
heart failure with antidiuretic hormone antagonists.
Vasopeptidase inhibitors such as omapatrilat
inhibit neutral endopeptidase (NEP).
Omapatrilat also inhibits angiotensin-conver-
ting enzyme ACE, thus causing vasodilatation. It
decreases the level of angiotensin II and inhibits the
degradation of bradykinin and natriuretic peptides.
The drug increases natriuresis, decreases vascular
wall tone, and inhibits proliferation of smooth mu-
scle cells. Attempts have been made to use omapa-
trilat in heart failure [18].
Adenosine receptor antagonists such as
BG9717 are candidate drugs for the treatment of
acute heart failure. Mechanisms involve dilation
of afferent renal arterioles, increased glomerular
filtration and improved renal function. Adenosine
receptor antagonists decrease sodium resorption
in the proximal and distal renal tubules, leading to
diuresis. In a randomised double-blind study pa-
tients with NYHA class II/III heart failure and pul-
monary oedema were given parenterally an ade-
nosine receptor antagonist combined with furose-
mide. Controls received only furosemide. The
combined treatment with BG9717 and furosemi-
de enhanced diuresis and creatinine clearance as
compared with the controls. Those receiving only
furosemide showed reduced creatinine clearance.
For this reason BG9717 may be especially benefi-
cial in patients with renal failure.
The development of new technologies in phar-
macology has resulted in the discovery of drugs that
may improve the prognosis and survival of patients
with acute heart failure. Further multi-centre and
randomised studies with these new drugs, if found
efficacious and safe, will provide the opportunity to
use them in the treatment of acute heart failure.
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